Predictive Value of Smoking Index Combined with NT-proBNP for Patients with Pulmonary Hypertension Due to Chronic Lung Disease: A Retrospective Study

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2024 Jun 10

PMID 38854590

Authors

Lin Sun

Xu Zhao

Yunting Guo

Xiaomin Hou

Jieru Li

Xiaoxia Ren

Lin Dong

Ruifeng Liang

Jisheng Nie

Yiwei Shi

Xiaojiang Qin

Affiliations

Soon will be listed here.

Abstract

Purpose: Smoking is a major risk factor for the group 3 PH. NT-proBNP is a biomarker for risk stratification in PH. This study aims to investigate the effects of smoking status and smoking index (SI) on group 3 PH and to evaluate the value of SI and SI combined with NT-proBNP in early diagnosis and prediction of disease severity.

Patients And Methods: Four hundred patients with group 3 PH at the First Hospital of Shanxi Medical University between January 2020 and December 2021 were enrolled and divided into two groups: mild (30 mmHg ≤ pulmonary artery systolic pressure (PASP)≤50 mmHg) and non-mild (PASP >50 mmHg). The effect of smoking on group 3 PH was analyzed using univariate analysis, and logistic analysis was conducted to evaluate the risk of group 3 PH according to smoking status and SI. Spearman correlation coefficient was used to test the correlation between SI and the index of group 3 PH severity. The predictive value of SI was evaluated using a receiver operating characteristic (ROC) curve.

Results: Correlation and logistic analyses showed that SI was associated with PH severity. Smoking status =0.009) and SI (=0.039) were independent risk factors for non-mild group 3 PH, and ROC showed that the predictive value of SI (AUC:0.596) for non-mild PH was better than that of the recognized pro-brain natriuretic peptide (NT-proBNP) (AUC:0.586). SI can be used as a single predictive marker. SI and NT-proBNP can be formulated as prediction models for screening non-mild clinical cases (AUC:0.628).

Conclusion: SI is a potentially ideal non-invasive predictive marker for group 3 PH. SI and NT-proBNP could be used to develop a prediction model for screening non-mild PH cases. This can greatly improve the predictive specificity of the established PH marker, NT-proBNP.

References

Luppi F, Kalluri M, Faverio P, Kreuter M, Ferrara G . Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. Respir Res. 2021; 22(1):109. PMC: 8052779. DOI: 10.1186/s12931-021-01711-1. View

Johnson A, Nystrom N, Piper M, Cook J, Norton D, Zuelsdorff M . Cigarette Smoking Status, Cigarette Exposure, and Duration of Abstinence Predicting Incident Dementia and Death: A Multistate Model Approach. J Alzheimers Dis. 2021; 80(3):1013-1023. PMC: 8044009. DOI: 10.3233/JAD-201332. View

Lewis R, Durrington C, Condliffe R, Kiely D . BNP/NT-proBNP in pulmonary arterial hypertension: time for point-of-care testing?. Eur Respir Rev. 2020; 29(156). PMC: 9488846. DOI: 10.1183/16000617.0009-2020. View

Ruopp N, Cockrill B . Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022; 327(14):1379-1391. DOI: 10.1001/jama.2022.4402. View

Seimetz M, Parajuli N, Pichl A, Veit F, Kwapiszewska G, Weisel F . Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell. 2011; 147(2):293-305. DOI: 10.1016/j.cell.2011.08.035. View

Vonk Noordegraaf A, Chin K, Haddad F, Hassoun P, Hemnes A, Hopkins S . Pathophysiology of the right ventricle and of the pulmonary circulation in pulmonary hypertension: an update. Eur Respir J. 2018; 53(1). PMC: 6351344. DOI: 10.1183/13993003.01900-2018. View

Mandras S, Mehta H, Vaidya A . Pulmonary Hypertension: A Brief Guide for Clinicians. Mayo Clin Proc. 2020; 95(9):1978-1988. DOI: 10.1016/j.mayocp.2020.04.039. View

Pedersen K, Colak Y, Ellervik C, Hasselbalch H, Bojesen S, Nordestgaard B . Smoking and Increased White and Red Blood Cells. Arterioscler Thromb Vasc Biol. 2019; 39(5):965-977. DOI: 10.1161/ATVBAHA.118.312338. View

Qin X, Gao A, Hou X, Xu X, Chen L, Sun L . Connexins may play a critical role in cigarette smoke-induced pulmonary hypertension. Arch Toxicol. 2022; 96(6):1609-1621. DOI: 10.1007/s00204-022-03274-6. View

10.

Maries L, Manitiu I . Diagnostic and prognostic values of B-type natriuretic peptides (BNP) and N-terminal fragment brain natriuretic peptides (NT-pro-BNP). Cardiovasc J Afr. 2013; 24(7):286-9. PMC: 3807675. DOI: 10.5830/CVJA-2013-055. View

11.

Sevilla-Montero J, Munar-Rubert O, Pino-Fadon J, Aguilar-Latorre C, Villegas-Esguevillas M, Climent B . Cigarette smoke induces pulmonary arterial dysfunction through an imbalance in the redox status of the soluble guanylyl cyclase. Free Radic Biol Med. 2022; 193(Pt 1):9-22. DOI: 10.1016/j.freeradbiomed.2022.09.026. View

12.

Aldred M, Morrell N, Guignabert C . New Mutations and Pathogenesis of Pulmonary Hypertension: Progress and Puzzles in Disease Pathogenesis. Circ Res. 2022; 130(9):1365-1381. PMC: 9897592. DOI: 10.1161/CIRCRESAHA.122.320084. View

13.

Alkhedaide A . Tobacco smoking causes secondary polycythemia and a mild leukocytosis among heavy smokers in Taif City in Saudi Arabia. Saudi J Biol Sci. 2020; 27(1):407-411. PMC: 6933161. DOI: 10.1016/j.sjbs.2019.11.001. View

14.

Alqarni A, Brand O, Pasini A, Alahmari M, Alghamdi A, Pang L . Imbalanced prostanoid release mediates cigarette smoke-induced human pulmonary artery cell proliferation. Respir Res. 2022; 23(1):136. PMC: 9145181. DOI: 10.1186/s12931-022-02056-z. View

15.

Huang S . Knocking Out Smoking and Pulmonary Hypertension with a K. Am J Respir Crit Care Med. 2020; 203(10):1216-1218. PMC: 8456471. DOI: 10.1164/rccm.202011-4121ED. View

16.

Park J, Chang K, Park K, Choi S, Lee K, Lee J . Differential Effects between Cigarette Total Particulate Matter and Cigarette Smoke Extract on Blood and Blood Vessel. Toxicol Res. 2016; 32(4):353-358. PMC: 5080850. DOI: 10.5487/TR.2016.32.4.353. View

17.

Maron B, Abman S, Elliott C, Frantz R, Hopper R, Horn E . Pulmonary Arterial Hypertension: Diagnosis, Treatment, and Novel Advances. Am J Respir Crit Care Med. 2021; 203(12):1472-1487. PMC: 8483220. DOI: 10.1164/rccm.202012-4317SO. View

18.

Bauer-Kemeny C, Herth F . [Smoking-toxic substances and immunological consequences]. Radiologie (Heidelb). 2022; 62(9):731-737. DOI: 10.1007/s00117-022-01006-6. View

19.

Tang P . Clinical diagnostic value of circulating serum miR-509-3p in pulmonary arterial hypertension with congenital heart disease. Hellenic J Cardiol. 2018; 61(1):26-30. DOI: 10.1016/j.hjc.2018.06.004. View

20.

Schmitt W, Ruhs H, Burghaus R, Diedrich C, Duwal S, Eissing T . NT-proBNP Qualifies as a Surrogate for Clinical End Points in Heart Failure. Clin Pharmacol Ther. 2021; 110(2):498-507. PMC: 8360001. DOI: 10.1002/cpt.2222. View